RTP Mobile Logo
Submitted by jwr@researchtop... on Mon, 02/03/2020 - 15:52
BCU319

Track 1: Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC)
Track 2: Case (Dr Gubens): A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden
Track 3: Clinical care of patients with NSCLC brain metastases alone and no systemic disease
Track 4: Diagnosis of radiation necrosis
Track 5: Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases
Track 6: Mechanism of action of osimertinib in the brain and effect on CNS disease progression
Track 7: Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy
Track 8: Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs
Track 9: Case (Dr Gubens): A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases
Track 10: Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases
Track 11: Antitumor effect of ALK inhibitors in patients with CNS metastases
Track 12: Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression
Track 13: Managing CNS metastases with leptomeningeal involvement
Track 14: Case (Dr Gubens): A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement
Track 15: Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis
Track 16: Case (Dr Gubens): A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80%
Track 17: Outlook on the use of TKIs for patients with CNS metastases
Track 18: Potential for combining TKIs with chemotherapy in the management of CNS metastases
Track 19: Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies
 
FACULTY
 
Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida